Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971161 | 0.82 | CYP11B1 (0.56) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6969784 | 0.82 | QPCT (0.54) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL6979413 | 0.78 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2TBXAS1L3MBTL1 | |
| SCHEMBL10926330 | 0.76 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL771716 | 0.75 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL11279766 | 0.75 | CYP19A1 (0.67) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL11083222 | 0.75 | CYP19A1 (0.61) | CYP19A1CYP11B1CYP11B2TBXAS1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8307735 | 0.74 | CYP11B1 (0.97) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| Hydrochloric Acid SCHEMBL11082698 | 0.74 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1L3MBTL1 | |
| SCHEMBL11703283 | 0.73 | CYP19A1 (0.63) | CYP19A1CYP11B1CYP11B2TBXAS1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | CYP19A1 1823/4885CYP11B1 162/4885CYP11B2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.